|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Phase III clinical trial with a new oral contraceptive containing 150 |
| micrograms desogestrel and 20 micrograms ethinylestradiol. |
| Acta Obstetrica et Gynecologica Scandinavica. 1991;70(6):497-500. |
| Results are presented of a phase 3 international multicenter trial to study the effect of a new, low-dose oral |
| contraceptive (OC) containing 20 mcg ethinyl estradiol and 150 mcg desogestrel (Mercilon) with regard to efficacy, |
| cycle control, blood pressure, and acceptability. In total, 1684 women from 12 European countries were included in |
| the study. 4 pregnancies occurred, 3 of them patient failure and 1 tablet failure. The overall Pearl Index was 0.20. |
| The frequency of irregular bleeding was comparable to that recorded with other commonly used low-dose OCs. No |
| serious side effects occurred. The incidence of the most frequently reported subjective side effects, i.e., headache, |
| nausea, and breast tenderness, was already low after the 1st cycle of treatment and decreased to below pretreatment |
| levels with continued use. There was a small increase in mean body weight, which was confined essentially to |
| young women. The preparation did not affect the mean systolic or diastolic blood pressure. This new preparation |
| has thus far proven to be an effective, safe, and well-accepted ultra low-dose OC. (PubHealth.info Document ID: |
| PubHealth.info NOTE: The author(s) of this article titled, "Phase III clinical trial with a new oral contraceptive |
| containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol.", is(are) Lammers P; op ten Berg M. |
| The source of this article is "Acta Obstetrica et Gynecologica Scandinavica. 1991;70(6):497-500.". This article was |
| published in 1991 in English language(s). (PubHealth.info® Document ID: CONT3T 2011-06. All rights reserved with |
| PubHealth.info) PIN: 12011 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |